79 related articles for article (PubMed ID: 35427884)
1. The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.
Wibbeler E; Nickel M; Schwering C; Schulz A; Mink JW
Eur J Paediatr Neurol; 2022 May; 38():62-65. PubMed ID: 35427884
[TBL] [Abstract][Full Text] [Related]
2. Brain proton MR spectroscopy measurements in CLN3 disease.
Dang Do AN; Baker EH; Farmer CA; Soldatos AG; Thurm AE; Porter FD
Mol Genet Metab; 2023 May; 139(1):107584. PubMed ID: 37086568
[TBL] [Abstract][Full Text] [Related]
3. A diagnostic confidence scheme for CLN3 disease.
Masten MC; Corre C; Paciorkowski AR; Vierhile A; Adams HR; Vermilion J; Zimmerman GA; Augustine EF; Mink JW
J Inherit Metab Dis; 2021 Nov; 44(6):1453-1462. PubMed ID: 34453334
[TBL] [Abstract][Full Text] [Related]
4. Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis.
Hersrud SL; Kovács AD; Pearce DA
Biochim Biophys Acta; 2016 Jul; 1862(7):1324-36. PubMed ID: 27101989
[TBL] [Abstract][Full Text] [Related]
5. The parent and family impact of CLN3 disease: an observational survey-based study.
Schulz A; Patel N; Brudvig JJ; Stehr F; Weimer JM; Augustine EF
Orphanet J Rare Dis; 2024 Mar; 19(1):125. PubMed ID: 38500130
[TBL] [Abstract][Full Text] [Related]
6. Recognition and epileptology of protracted CLN3 disease.
Cameron JM; Damiano JA; Grinton B; Carney PW; McKelvie P; Silbert P; Lawn N; Scheffer IE; Oliver KL; Hildebrand MS; Berkovic SF
Epilepsia; 2023 Jul; 64(7):1833-1841. PubMed ID: 37039534
[TBL] [Abstract][Full Text] [Related]
7. A knock-in reporter model of Batten disease.
Eliason SL; Stein CS; Mao Q; Tecedor L; Ding SL; Gaines DM; Davidson BL
J Neurosci; 2007 Sep; 27(37):9826-34. PubMed ID: 17855597
[TBL] [Abstract][Full Text] [Related]
8. A recessive
Reith RR; Batt MC; Fuller AM; Meekins JM; Diehl KA; Zhou Y; Bedwell PS; Ward JA; Sanders SK; Petersen JL; Steffen DJ
J Vet Diagn Invest; 2024 May; 36(3):438-446. PubMed ID: 38516801
[TBL] [Abstract][Full Text] [Related]
9. CLN3 deficiency leads to neurological and metabolic perturbations during early development.
Heins-Marroquin U; Singh RR; Perathoner S; Gavotto F; Merino Ruiz C; Patraskaki M; Gomez-Giro G; Kleine Borgmann F; Meyer M; Carpentier A; Warmoes MO; Jäger C; Mittelbronn M; Schwamborn JC; Cordero-Maldonado ML; Crawford AD; Schymanski EL; Linster CL
Life Sci Alliance; 2024 Mar; 7(3):. PubMed ID: 38195117
[TBL] [Abstract][Full Text] [Related]
10. Assessing the integrity of auditory sensory memory processing in CLN3 disease (Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease)): an auditory evoked potential study of the duration-evoked mismatch negativity (MMN).
Brima T; Freedman EG; Prinsloo KD; Augustine EF; Adams HR; Wang KH; Mink JW; Shaw LH; Mantel EP; Foxe JJ
J Neurodev Disord; 2024 Jan; 16(1):3. PubMed ID: 38183037
[TBL] [Abstract][Full Text] [Related]
11. Natural History of Neuronal Ceroid Lipofuscinosis Type 6, Late Infantile Disease.
O'Neal M; Noher de Halac I; Aylward SC; Yildiz V; Zapanta B; Abreu N; de Los Reyes E
Pediatr Neurol; 2024 May; 154():51-57. PubMed ID: 38531163
[TBL] [Abstract][Full Text] [Related]
12. The Batten disease protein CLN3 is important for stress granules dynamics and translational activity.
Relton EL; Roth NJ; Yasa S; Kaleem A; Hermey G; Minnis CJ; Mole SE; Shelkovnikova T; Lefrancois S; McCormick PJ; Locker N
J Biol Chem; 2023 May; 299(5):104649. PubMed ID: 36965618
[TBL] [Abstract][Full Text] [Related]
13. Developmental Skills and Neurorehabilitation for Children With Batten Disease: A Retrospective Chart Review of a Comprehensive Batten Clinic.
Bican R; Goddard V; Abreu N; Peifer D; Basinger A; Sveda M; Tanner K; de Los Reyes EC
Pediatr Neurol; 2024 Mar; 152():107-114. PubMed ID: 38242022
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression alters disease severity in juvenile Batten disease mice.
Seehafer SS; Ramirez-Montealegre D; Wong AM; Chan CH; Castaneda J; Horak M; Ahmadi SM; Lim MJ; Cooper JD; Pearce DA
J Neuroimmunol; 2011 Jan; 230(1-2):169-72. PubMed ID: 20937531
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid Protein Biomarker Discovery in CLN3.
Dang Do AN; Sleat DE; Campbell K; Johnson NL; Zheng H; Wassif CA; Dale RK; Porter FD
J Proteome Res; 2023 Jul; 22(7):2493-2508. PubMed ID: 37338096
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype.
Soldati C; Lopez-Fabuel I; Wanderlingh LG; Garcia-Macia M; Monfregola J; Esposito A; Napolitano G; Guevara-Ferrer M; Scotto Rosato A; Krogsaeter EK; Paquet D; Grimm CM; Montefusco S; Braulke T; Storch S; Mole SE; De Matteis MA; Ballabio A; Sampaio JL; McKay T; Johannes L; Bolaños JP; Medina DL
EMBO Mol Med; 2021 Oct; 13(10):e13742. PubMed ID: 34411438
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide signaling is disrupted in the yeast model for Batten disease.
Osório NS; Carvalho A; Almeida AJ; Padilla-Lopez S; Leão C; Laranjinha J; Ludovico P; Pearce DA; Rodrigues F
Mol Biol Cell; 2007 Jul; 18(7):2755-67. PubMed ID: 17475770
[TBL] [Abstract][Full Text] [Related]
18. Oligoantigenic Diet Improves Children's ADHD Rating Scale Scores Reliably in Added Video-Rating.
Dölp A; Schneider-Momm K; Heiser P; Clement C; Rauh R; Clement HW; Schulz E; Fleischhaker C
Front Psychiatry; 2020; 11():730. PubMed ID: 32973571
[TBL] [Abstract][Full Text] [Related]
19. Plasma biomarkers for neuronal ceroid lipofuscinosis.
Hersrud SL; Geraets RD; Weber KL; Chan CH; Pearce DA
FEBS J; 2016 Feb; 283(3):459-71. PubMed ID: 26565144
[TBL] [Abstract][Full Text] [Related]
20. Treatment of non-epileptic episodes of anxious, fearful behavior in adolescent juvenile neuronal ceroid lipofuscinosis (CLN3 disease).
Ostergaard JR
Front Neurol; 2023; 14():1216861. PubMed ID: 37771451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
